Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

MCT Focus: Developmental Therapeutics in Radiation Oncology

A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers

Jie Du, Jun Shang, Fei Chen, Yushuo Zhang, Narui Yin, Ting Xie, Haowen Zhang, Jiahua Yu and Fenju Liu
Jie Du
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Shang
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fei Chen
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yushuo Zhang
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Narui Yin
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ting Xie
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Haowen Zhang
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiahua Yu
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: radiobiology@126.com yujiahua@suda.edu.cn
Fenju Liu
Department of Radiobiology, School of Radiation Medicine and Protection, Medical College of Soochow University, School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Suzhou, China.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: radiobiology@126.com yujiahua@suda.edu.cn
DOI: 10.1158/1535-7163.MCT-17-0090 Published February 2018
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Quantitative detection of sgHPRT-induced mutation by HRM analysis. A, Graphical representation of the targeting of HPRT locus using CRISPR/Cas9 system. B, HEK293T cells were transfected with sgHPRT plasmid, and genomic DNA was extracted at different time points. T7E1 cleavage assay was performed to evaluate the targeted mutation. C, Melting data were collected and normalized as described in Materials and Methods (top), and a subtractive plot showed the relative fluorescence difference (ΔF) to the control curve (bottom). D, Different mutation efficiencies were induced by transfection of proportional sgHPRT and control plasmid. The data were presented in a three-dimension plot where x-axis showed the temperature, y-axis showed the ΔF, and z-axis showed the mutation efficiency. E, Correlation of the mutation efficiency with the maximum value of ΔF (ΔFmax).

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Design and validation of the screening for NHEJ inhibitors. A, Schematic depicting the screening procedures. HEK293T cells were transfected with sgHPRT plasmid for 5 hours, and subcultured into 96-well plates in the presence of the screening compounds. Twenty-four hours later, genomic DNA was extracted and subjected to HRM analysis. Two DNA-PKcs inhibitors, NU7441 and KU-0060648, were incubated with cells in 96-well plates. Three-dimensional plots show the HRM data of different concentrations of NU7441 (B) and KU-0060648 (D). Linear correlation between the concentrations and ΔFmax for NU7441 (C) and KU-0060648 (E).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Results of the screening of an approved drug library. A, The drugs were classified according to their pharmacologic action. The composition of the 10 categories was shown in the circle chart. B, Scatter plots of the screening results of 1,540 compounds. Tables of top hits of Category no. 7 (cardiovascular system; C) and Category no. 8 (nervous system; D).

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Dose–response analysis of the screening hits. The chemical structures, and the cytotoxic and NHEJ-inhibiting effects of ouabain (A) and penfluridol (B) were shown in a dose-dependent manner. HEK293T cells were treated with different concentration of ouabain or penfluridol for 24 hours. C, Measurement of NHEJ and HR activities by using the NHEJ and HR reporter plasmids. HEK293T cells were transfected with I-SceI–linearized plasmids and incubated with ouabain or penfluridol for 24 hours. A DsRed-expressing plasmid was cotransfected as transfection control. Recircularized plasmids by NHEJ or HR have the intact GFP gene that can be assayed by flow cytometry. *, P < 0.05; **, P < 0.01 versus DMSO-treated group, n = 4.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Radiosensitizing effects of ouabain and penfluridol. A, HeLa cells were incubated with 0.1 μmol/L ouabain or 5 μmol/L penfluridol for 2 hours, then exposed to 8 Gy of X-ray, and further incubated with these drugs for 3 hours. Neutral comet assay was performed 12 hours postirradiation. B, The percentage of DNA content in the tails were analyzed; *, P < 0.05 versus DMSO-treated group, n = 3. Representative images of the colony formation assay of ouabain (C) and penfluridol (E) were shown. Treatment of ouabain (D) and penfluridol (F) increased the radiosensitivity of HeLa cells. *, P < 0.05 versus DMSO-treated group, n = 3.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Impairment of DSB repair by ouabain and penfluridol. A, HeLa cells were incubated with 0.1 μmol/L ouabain or 5 μmol/L penfluridol for 2 hours, then exposed to 8 Gy of X-ray, and further incubated with these drugs for 3 hours. Twelve hours postirradiation, γH2AX and 53BP1 foci formations were visualized by immunofluorescent staining. B, Four hours postirradiation, the expressions of phosphorylated DNA-PKcs, ATM, and Chk2 were analyzed by Western blotting. *, P < 0.05 versus DMSO-treated group, n = 3.

Additional Files

  • Figures
  • Supplementary Data

    • Supplementary Figures S1-S4 and Supplementary Methods - Figure S1: HRM analysis of the sgHBEGF-induced mutation; Figure S2: Figure S3: Selected hits of NHEJ inhibitors; Figure S4: The direct effects of ouabain and penfluridol on DNA-PK were examined by using DNA-PK activity assayin vitro.
    • Table S1 - Full table of the screening results.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 17 (2)
February 2018
Volume 17, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers
Jie Du, Jun Shang, Fei Chen, Yushuo Zhang, Narui Yin, Ting Xie, Haowen Zhang, Jiahua Yu and Fenju Liu
Mol Cancer Ther February 1 2018 (17) (2) 419-431; DOI: 10.1158/1535-7163.MCT-17-0090

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers
Jie Du, Jun Shang, Fei Chen, Yushuo Zhang, Narui Yin, Ting Xie, Haowen Zhang, Jiahua Yu and Fenju Liu
Mol Cancer Ther February 1 2018 (17) (2) 419-431; DOI: 10.1158/1535-7163.MCT-17-0090
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • A Radioprotective Agonist for p53 Transactivation
  • Arginine Deprivation Radiosensitizes Glioblastoma Cells
  • Normal Tissue Sparing by HDAC Inhibition with IR
Show more MCT Focus: Developmental Therapeutics in Radiation Oncology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement